DOCSLIB.ORG

Mirnas Documented to Play a Role in Hematopoietic Cell Lineage. Our

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Table S1: miRNAs documented to play a role in hematopoietic cell lineage. Our review of the literature summarizing miRNAs known to be involved in the development and proliferation of the hematopoietic lineage cells. miRNA Expression/function/target/regulator References miR-150 Elevated during developmental stages of B and T cell maturation. 16-19 Controls B cell differentiation, present in mature, resting T and B cells but decreased upon activation of naïve T or B cells. Plays a role in establishing lymphocyte identity. Very little is known about function in T cells. Regulators: Foxp3 Target: C-Myb miR-146a/b Upregulated in macropgahe inflammatory response. Differentially 17, 20 upregulated in murine Th1 subset but abolished in Th2 subset. Upregulated in response to TCRs stimulation, as well as by IL-1 and TNF. Highly expressed in murine T-regs and could play a role in establishing lymphocyte identity. Modulates activation induced cell death in activated T cells. Negative regulator of TLR and cytokine signaling pathway. Endotoxin tolerance. Antiviral role. Targets: IRAK1, IRAK2, TRAF6, FAF1 miR-16-1 Promote apoptosis by targeting Bcl2 expression, act as tumor 22 cluster suppressor RNAs. May block differentiation of later stage hematopoietic progenitor cells to mature cells. Downregulated in CLL. Target: BCL2. miR-155 Regulator of T and B cell maturation and innate immune response. 23-29 Expressed in primary mediastinal B-cell lymphoma, T and B cells, macrophages and DCs. Upregulated during B cell activation. Involved in T cell differentiation and indicated as a positive regulator of cytokine production. Activated by stimulating TLR3 and INFab receptors in bone derived macrophages (regulation of antimicrobial defense). Associated with EBV latency type-III infection. Targets: AGTR1, PU.1, c-Maf. SHIP1, AID, SOSC1, BACH1, CEBPB, CSFR, TAB2, MAF, JARID2 Regulators: FOXP3 in Tregs, C-MYC in B cells, AP-1 and NF-kB miR-17-92 Consists of miR-17, -18a, -19a, -20a, -19b-1,–92-1, and 106a. 30-33 cluster: Over-expressed in lymphomas and other hematological miR-17 malignancies, suppress cell death, increase lymphogenesis, miR-18a regulator of T and B cell development, inhibit monocyte miR-19a proliferation, differentiation and maturation. miR-20a Targets: E2F1, BIM, PTEN, IL10 miR-19b Regulator: C-MYC miR-92a miR-106a miR-32 Direct negative effect on replication of PFV-1 virus by 21 downregulating of replication-essential viral proteins encoded by ORF2 miR-132 CREB-responsive gene that regulates neuronal outgrowth in rats by 34-35 controlling p250GAP protein expression. Endotoxin-responsive gene, LPS signaling. Differentially unregulated in six solid cancer types. Megakaryocytic differentiation miR-181a B and T cell Hematopoiesis. Positive regulator for B cell 36-37 differentiation, tentative negative T cell development regulator. Regulates sensitivity of T-cell Receptor, regulates T cell selection during thymic development, present in immature thymocytes. Changes in miR-181a levels might function as a rheostat by regulating protein phosphorylation levels. Targets:TCL1, HOXA11, DUSP5, DUSP6, SHP2 and PTPN22 miR-181b Implicated in regulation of B cell function by affecting class- 38 switching recombination miR-181c Human activated CD4(+) T lymphocytes increase IL-2 expression 39 by downregulating microRNA-181c. miR-181c was proven to have the potential to regulate CD4(+) T cell activation. miR-181c was downregulated in the process of CD4(+) T cell activation, can bind to the IL-2 3' UTR and repress its expression by inhibiting translation. Moreover, miR-181c mimics reduced activated CD4(+) T cell proliferation. miR-142 Early hematopoietic development, T-cell lineage, translocated in 40-41, 18 miR-142-3p B-PLL patients. Expressed in Tregs, repressed by FOXP3, leading to increased production of cyclic AMP and suppressor function of T-reg cells. Target: AC9 miR-223 Expression in T-lineage cells, negative regulator of neutrophil 41-43 proliferation and activation, enhances T cell differentiation. Targets: Mef2c, IGFR Regulators: PU.1, C/EBP alpha, NFI-A miR-221 Highly-expressed in human cord-blood derived hematopoietic 44-45 miR-222 CD34+ progenitor cells. Down regulated in response to erythroid lineage differentiation. Controls terminal stages in hematopoietic development. Target: c-kit miR-214 Targets Pten in activated murine T cells and its expression leads to 46 increased T cell proliferation in mice. Furthermore, upregulation of miR-214 was dependent on CD28 costimulation Target: Pten miR-24 miR-24 is consistently upregulated during terminal differentiation 47 of hematopoietic cell lines into a variety of lineages, miR-24 is also upregulated during thymic development to naive CD8 T cells. miR-103 Block differentiation of hematopoietic stem-progenitor cells 48 miR-107 (HSPC) at a later stage in HSPC development miR-29 Linked with aggressive CLL phenotype. 49 Target: TCL1 miR-LET-7e Upregulated in APL patients upon retinoic acid treatment 50 mIR-342 miR-130a Megakaryocytic differentiation. 50 Target: MAFB miR-21 Upregulated during macrophage inflammatory response. MiR-21 51-53 miR-147 upregulated in CD4+ T cells upon IL-21 stimulation and regulated miR-9 by STAT3. In peripheral human monocytes and neutrophils miR-9 is similarly upregulated by pro-inflammatory signals. Target: BCL2 miR-144 Direct targets of the critical hematopoietic transcription factor 54 miR-451 GATA-1. Required for erythropoiesis miR-129 Targets genes related to miRNAs processing or transcription 55 regulation miR-520h May promote differentiation of HSCs into progenitor cells by 55 inhibiting ABCG2 expression miR-125b Expressed in centroblasts and shown to repress PRDM1 and IRF4 55 miR-125b-1 Involved in translocation in B-ALL case 56 miR-122 Required for hepatitis C proliferation in liver 57 miR-10 miR-196b is regulated by the HSC transcription factor family 58-60 miR-196b mixed lineage leukaemia (MLL), and has a functional role in miR-126 modulating HSC homeostasis and lineage commitment, could directly repress HOX family expression, important roles in regulating HSC homeostasis. miR-126 has also been shown to regulate expression of HOXA9 and PLK2 miR-326 Expressed in T cells, promotes TH17 cell development both in 61 vitro and in vivo by targeting ETS1 miR-101 Differentially expressed in human naive, memory and TFH CD4+ 62-63 cells and inversely correlates to ICOS expression in these subsets, with the highest levels found in naive (ICOSneg) cells, intermediate levels in memory cells (ICOSint) and lowest levels in TFH cells (ICOShigh) miR-184 Inhibits NFAT1 protein expression elicited by UCB CD4+ T cells. 64 Endogenous expression of miR-184 in UCB is 58.4-fold higher compared with AB CD4+ T cells, and miR-184 blocks production of NFAT1 protein through its complementary target sequence on the NFATc2 mRNA without transcript degradation. avg-T0 log2_fold- fold- rawp- adjp- Symbol Ensembl_gene Definition log2 avg-T48 log2 T48_vs_T0 T48_vs_T0 T48_vs_T0 T48_vs_T0 ANOVA-rawp ANOVA-adjp largest fold #Mirs Mir List (includes only miRs upregulated as determined by t-test) Proto-oncogene protein c-fos (Cellular oncogene fos)(G0/G1 switch FOS ENSG00000170345 regulatory protein 7) [Source:UniProtKB/Swiss-Prot;Acc:P01100] 10.24 6.08 -4.16 -17.86 4.87E-15 5.13E-12 4.58E-28 4.10E-24 4.69 2 hsa-miR-155,hsa-miR-221, Dual specificity protein phosphatase 1 (EC 3.1.3.48)(EC 3.1.3.16)(MAP kinase phosphatase 1)(MKP-1)(Protein-tyrosine phosphatase CL100)(Dual specificity protein phosphatase hVH1) DUSP1 ENSG00000120129 [Source:UniProtKB/Swiss-Prot;Acc:P28562] 10.79 7.09 -3.70 -13.03 2.72E-11 4.94E-09 2.91E-21 2.54E-18 4.32 1 hsa-miR-200b, Protein fosB (G0/G1 switch regulatory protein 3) FOSB ENSG00000125740 [Source:UniProtKB/Swiss-Prot;Acc:P53539] 9.00 6.04 -2.96 -7.79 3.22E-14 2.31E-11 1.84E-26 1.10E-22 3.36 1 hsa-miR-27a, Integrin alpha-6 Precursor (VLA-6)(CD49 antigen-like family member F)(CD49f antigen) [Contains Integrin alpha-6 heavy chain;Integrin ITGA6 ENSG00000091409 alpha-6 light chain] [Source:UniProtKB/Swiss-Prot;Acc:P23229] 7.94 5.09 -2.85 -7.20 1.15E-08 6.54E-07 3.42E-15 3.26E-13 3.25 2 hsa-miR-19a,hsa-miR-29b, Krueppel-like factor 3 (Basic krueppel-like factor)(CACCC-box- binding protein BKLF)(TEF-2) [Source:UniProtKB/Swiss- hsa-miR-130b,hsa-miR-132,hsa-miR-135b,hsa-miR-155,hsa-miR-20a,hsa-miR- KLF3 ENSG00000109787 Prot;Acc:P57682] 8.69 6.02 -2.67 -6.38 3.50E-09 2.46E-07 3.67E-16 4.61E-14 2.87 9 218,hsa-miR-221,hsa-miR-27a,hsa-miR-365, Nuclear receptor subfamily 4 group A member 2 (Orphan nuclear receptor NURR1)(Immediate-early response protein NOT)(Transcriptionally-inducible nuclear receptor) NR4A2 ENSG00000153234 [Source:UniProtKB/Swiss-Prot;Acc:P43354] 9.57 7.04 -2.53 -5.77 2.88E-07 8.90E-06 9.78E-14 6.06E-12 3.31 4 hsa-miR-132,hsa-miR-200b,hsa-miR-206,hsa-miR-365, V-set and immunoglobulin domain-containing protein 1 Precursor (Cell surface A33 antigen)(Glycoprotein A34) VSIG1 ENSG00000101842 [Source:UniProtKB/Swiss-Prot;Acc:Q86XK7] 6.69 4.20 -2.50 -5.64 2.16E-07 7.08E-06 1.69E-15 1.73E-13 2.89 2 hsa-miR-155,hsa-miR-365, Thioredoxin-interacting protein (Vitamin D3 up-regulated protein 1)(Thioredoxin-binding protein 2) [Source:UniProtKB/Swiss- TXNIP ENSG00000117289 Prot;Acc:Q9H3M7] 10.18 7.70 -2.48 -5.56 8.44E-08 3.26E-06 5.01E-13 2.47E-11 2.77 1 hsa-miR-18a, Cytochrome b-245 heavy chain (EC 1.-.-.-)(p22 phagocyte B- cytochrome)(Neutrophil cytochrome b 91 kDa polypeptide)(Heme- binding membrane glycoprotein gp91phox)(CGD91-phox)(gp91- phox)(gp91-1)(Cytochrome b(558)
Recommended publications
  • Human CD64 / FCGR1A Protein (His Tag), Biotinylated

    Human CD64 / FCGR1A Protein (His Tag), Biotinylated

    Human CD64 / FCGR1A Protein (His Tag), Biotinylated Catalog Number: 10256-H08S-B General Information SDS-PAGE: Gene Name Synonym: CD64; Fc gamma RI Protein Construction: A DNA sequence encoding the human FCGR1A (NP_000557.1) (Met1- Pro288) was expressed with a polyhistidine tag at the C-terminus. The purified protein was biotinylated in vitro. Source: Human Expression Host: CHO Stable Cells QC Testing Purity: > 95 % as determined by SDS-PAGE. Bio Activity： Protein Description Measured by its binding ability in a functional ELISA.Immobilized High affinity immunoglobulin gamma Fc receptor I, also known as FCGR1 biotinylated Human CD64 Protein (Cat：10256-H08S-B)at 10 μg/mL can and CD64, is an integral membraneglycoprotein and a member of the bind human IgG1,The EC50 of human IgG1 is 6-14 ng/mL. immunoglobulin superfamily. CD64 is a high affinity receptor for the Fc region of IgG gamma and functions in both innate and adaptive immune Endotoxin: responses. Receptors that recognize the Fc portion of IgG function in the regulation of immune response and are divided into three classes < 1.0 EU per μg protein as determined by the LAL method. designated CD64, CD32, and CD16. CD64 is structurally composed of asignal peptidethat allows its transport to the surface of a cell, Stability: threeextracellularimmunoglobulin domainsof the C2-type that it uses to Samples are stable for up to twelve months from date of receipt at -70 ℃ bind antibody, a hydrophobictransmembrane domain, and a short cytoplasmic tail. CD64 isconstitutivelyfound on only macrophages and Predicted N terminal: Gln 16 monocytes, but treatment of polymorphonuclear leukocyteswith cytokines likeIFNγandG-CSFcan induce CD64 expression on these cells.
  • Yeast DNA Polymerase Zeta (␨)Is Essential for Error-Free Replication Past Thymine Glycol

    Yeast DNA Polymerase Zeta (␨)Is Essential for Error-Free Replication Past Thymine Glycol

    Downloaded from genesdev.cshlp.org on September 24, 2021 - Published by Cold Spring Harbor Laboratory Press Yeast DNA polymerase zeta (␨)is essential for error-free replication past thymine glycol Robert E. Johnson, Sung-Lim Yu, Satya Prakash, and Louise Prakash1 Sealy Center for Molecular Science, University of Texas Medical Branch at Galveston, Galveston, Texas 77555-1061, USA DNA polymerase zeta (Pol␨) promotes the mutagenic bypass of DNA lesions in eukaryotes. Genetic studies in Saccharomyces cerevisiae have indicated that relative to the contribution of other pathways, Pol␨ makes only a modest contribution to lesion bypass. Intriguingly, however, disruption of the REV3 gene, which encodes the catalytic subunit of Pol␨, causes early embryonic lethality in mice. Here, we present genetic and biochemical evidence for the requirement of yeast Pol␨ for predominantly error-free replication past thymine glycol (Tg), a DNA lesion formed frequently by free radical attack. These results raise the possibility that, as in yeast, in higher eukaryotes also, Pol␨ makes a major contribution to the replicative bypass of Tgs as well as other lesions that block synthesis by replicative DNA polymerases. Such a preeminent role of Pol␨ in lesion bypass would ensure that rapid cell divisions continue unabated during early embryonic development, thereby minimizing the generation of DNA strand breaks, chromosome aberrations, and the ensuing apoptotic response. [Keywords: DNApolymerase ␨; thymine glycol; translesion DNAsynthesis; Pol ␨ as an extender; error-free translesion DNAsynthesis by Pol ␨; yeast] Received October 4, 2002; revised version accepted October 31, 2002. Genetic studies in the yeast Saccharomyces cerevisiae et al. 2000b; Washington et al. 2000). Genetic studies in have indicated the requirement of Rad6–Rad18-depen- yeast have additionally indicated a role for Pol␩ in the dent processes in promoting replication of damaged error-free bypass of cyclobutane pyrimidine dimers DNA.
  • Dissert 1 Title

    Dissert 1 Title

    GENETIC AND BIOCHEMICAL ANALYSIS OF ESSENTIAL ENZYMES IN TRIACYLGLYCEROL SYNTHESIS IN ARABIDOPSIS By KIMBERLY LYNN COTTON A dissertation submitted in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY WASHINGTON STATE UNIVERSITY Molecular Plant Sciences DECEMBER 2015 © Copyright by KIMBERLY LYNN COTTON, 2015 All Rights Reserved To the Faculty of Washington State University: The members of the Committee appointed to examine the dissertation of KIMBERLY LYNN COTTON find it satisfactory and recommend that it be accepted. ____________________________________________ John A. Browse, Ph.D., Chair _____________________________________________ Michael M. Neff, Ph.D. _____________________________________________ Thomas W. Okita, Ph.D. _____________________________________________ John J. Wyrick, Ph.D. ii ACKNOWLEDGMENTS To my PI John Browse, thank you for your support, guidance and patience over the years. To my committee, John Browse, Michael Neff, Thomas Okita, and John Wyrick, thank you for your insightful discussions and suggestions. To my collaborators Jay Shockey, Anushobha Regmi, Neil Adhikari, John Browse, and Phil Bates, thanks for the great work and great times. To Browse Lab members past and present, thanks for the help, guidance and wonderful memories. To the undergraduate students who have helped me over the years, thank you for all your help in making this project possible; and with a special thank you to Arlene, Tesa, Breana, and “no-longer-undergrads” David and Barbara Cotton for their particular dedication to this project. And finally, a huge thank you to my family and friends who have loved and supported me throughout this venture. Go Cougs! iii GENETIC AND BIOCHEMICAL ANALYSIS OF ESSENTIAL ENZYMES IN TRIACYLGLYCEROL SYNTHESIS IN ARABIDOPSIS Abstract by Kimberly Lynn Cotton, Ph.D.
  • Aggf1 Attenuates Neuroinflammation and BBB Disruption Via PI3K/Akt/NF-Κb Pathway After Subarachnoid Hemorrhage in Rats

    Aggf1 Attenuates Neuroinflammation and BBB Disruption Via PI3K/Akt/NF-Κb Pathway After Subarachnoid Hemorrhage in Rats

    Zhu et al. Journal of Neuroinflammation (2018) 15:178 https://doi.org/10.1186/s12974-018-1211-8 RESEARCH Open Access Aggf1 attenuates neuroinflammation and BBB disruption via PI3K/Akt/NF-κB pathway after subarachnoid hemorrhage in rats Qiquan Zhu1,2, Budbazar Enkhjargal2, Lei Huang2,4, Tongyu Zhang2, Chengmei Sun2, Zhiyi Xie2, Pei Wu2, Jun Mo2, Jiping Tang2, Zongyi Xie1* and John H. Zhang2,3,4* Abstract Background: Neuroinflammation and blood-brain barrier (BBB) disruption are two critical mechanisms of subarachnoid hemorrhage (SAH)-induced brain injury, which are closely related to patient prognosis. Recently, angiogenic factor with G-patch and FHA domain 1 (Aggf1) was shown to inhibit inflammatory effect and preserve vascular integrity in non-nervous system diseases. This study aimed to determine whether Aggf1 could attenuate neuroinflammation and preserve BBB integrity after experimental SAH, as well as the underlying mechanisms of its protective roles. Methods: Two hundred forty-nine male Sprague-Dawley rats were subjected to the endovascular perforation model of SAH. Recombinant human Aggf1 (rh-Aggf1) was administered intravenously via tail vein injection at 1 h after SAH induction. To investigate the underlying neuroprotection mechanism, Aggf1 small interfering RNA (Aggf1 siRNA) and PI3K-specific inhibitor LY294002 were administered through intracerebroventricular (i.c.v.) before SAH induction. SAH grade, neurological score, brain water content, BBB permeability, Western blot, and immunohistochemistry were performed. Results: Expression of endogenous Aggf1 was markedly increased after SAH. Aggf1 was primarily expressed in endothelial cells and astrocytes, as well as microglia after SAH. Administration of rh-Aggf1 significantly reduced brain water content and BBB permeability, decreased the numbers of infiltrating neutrophils, and activated microglia in the ipsilateral cerebral cortex following SAH.
  • The Title of the Dissertation

    The Title of the Dissertation

    UNIVERSITY OF CALIFORNIA SAN DIEGO Novel network-based integrated analyses of multi-omics data reveal new insights into CD8+ T cell differentiation and mouse embryogenesis A dissertation submitted in partial satisfaction of the requirements for the degree Doctor of Philosophy in Bioinformatics and Systems Biology by Kai Zhang Committee in charge: Professor Wei Wang, Chair Professor Pavel Arkadjevich Pevzner, Co-Chair Professor Vineet Bafna Professor Cornelis Murre Professor Bing Ren 2018 Copyright Kai Zhang, 2018 All rights reserved. The dissertation of Kai Zhang is approved, and it is accept- able in quality and form for publication on microfilm and electronically: Co-Chair Chair University of California San Diego 2018 iii EPIGRAPH The only true wisdom is in knowing you know nothing. —Socrates iv TABLE OF CONTENTS Signature Page ....................................... iii Epigraph ........................................... iv Table of Contents ...................................... v List of Figures ........................................ viii List of Tables ........................................ ix Acknowledgements ..................................... x Vita ............................................. xi Abstract of the Dissertation ................................. xii Chapter 1 General introduction ............................ 1 1.1 The applications of graph theory in bioinformatics ......... 1 1.2 Leveraging graphs to conduct integrated analyses .......... 4 1.3 References .............................. 6 Chapter 2 Systematic
  • Integrated and Functional Genomic Approaches to Elucidate Differential Genetic Dependencies in Melanoma

    Integrated and Functional Genomic Approaches to Elucidate Differential Genetic Dependencies in Melanoma

    Integrated and Functional Genomic Approaches to Elucidate Differential Genetic Dependencies in Melanoma The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Wong, Terence. 2018. Integrated and Functional Genomic Approaches to Elucidate Differential Genetic Dependencies in Melanoma. Doctoral dissertation, Harvard University, Graduate School of Arts & Sciences. Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:42014990 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Integrated and Functional Genomic Approaches to Elucidate Differential Genetic Dependencies in Melanoma A dissertation presented by Terence Cheng Wong to The Division of Medical Sciences in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the subject of Biological and Biomedical Sciences Harvard University Cambridge, Massachusetts November 2017 © 2017 Terence Cheng Wong All rights reserved. Dissertation Advisor: Levi Garraway Terence Cheng Wong Integrated and Functional Genomic Approaches to Elucidate Differential Genetic Dependencies in Melanoma ABSTRACT Genomic characterization of human cancers over the past decade has generated comprehensive catalogues of genetic alterations in cancer genomes. Many of these genetic events result in molecular or cellular changes that drive cancer cell phenotypes. In melanoma, a majority of tumors harbor mutations in the BRAF gene, leading to activation of the MAPK pathway and tumor initiation. The development and use of drugs that target the mutant BRAF protein and the MAPK pathway have produced significant clinical benefit in melanoma patients.
  • 32-3824: FDX1 Recombinant Protein Description Product Info

    32-3824: FDX1 Recombinant Protein Description Product Info

    ABGENEX Pvt. Ltd., E-5, Infocity, KIIT Post Office, Tel : +91-674-2720712, +91-9437550560 Email : [email protected] Bhubaneswar, Odisha - 751024, INDIA 32-3824: FDX1 Recombinant Protein Alternative Name : Adrenodoxin mitochondrial,Adrenal ferredoxin,Ferredoxin-1,Hepatoredoxin,FDX1,ADX. Description Source : Escherichia Coli. FDX1 Human Recombinant fused with a 15 amino acid T7 tag at N-terminus produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 139 amino acids (61-184 a.a.) and having a molecular mass of 15.0kDa.The FDX1 is purified by proprietary chromatographic techniques. Ferredoxin-1 is a small iron-sulfur protein who transfers electrons from NADPH through ferredoxin reductase to a terminal cytochrome P450. This specific oxidation/reduction system is located in steroidogenic tissues, and is involved with the synthesis of bile acid and vitamin D. FDX1 takes part in the synthesis of thyroid hormones and transfers electrons from adrenodoxin reductase to the cholesterol side chain cleavage cytochrome P450. FDX1 supports reactions catalyzed by human microsomal P450s- full length CYP17, truncated CYP17, and truncated CYP21. In addition to the FDX1 at the 11q22chromosomal locus, there are pseudogenes located on chromosomes 20 and 21. Product Info Amount : 25 µg Purification : Greater than 90.0% as determined by SDS-PAGE. Content : The FDX1 solution contains 20mM Tris-HCl buffer (pH8.0) and 10% Glycerol. Store at 4°C if entire vial will be used within 2-4 weeks. Store, frozen at -20°C for longer periods of Storage condition : time. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).Avoid multiple freeze-thaw cycles.
  • The Endocytic Membrane Trafficking Pathway Plays a Major Role

    The Endocytic Membrane Trafficking Pathway Plays a Major Role

    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by University of Liverpool Repository RESEARCH ARTICLE The Endocytic Membrane Trafficking Pathway Plays a Major Role in the Risk of Parkinson’s Disease Sara Bandres-Ciga, PhD,1,2 Sara Saez-Atienzar, PhD,3 Luis Bonet-Ponce, PhD,4 Kimberley Billingsley, MSc,1,5,6 Dan Vitale, MSc,7 Cornelis Blauwendraat, PhD,1 Jesse Raphael Gibbs, PhD,7 Lasse Pihlstrøm, MD, PhD,8 Ziv Gan-Or, MD, PhD,9,10 The International Parkinson’s Disease Genomics Consortium (IPDGC), Mark R. Cookson, PhD,4 Mike A. Nalls, PhD,1,11 and Andrew B. Singleton, PhD1* 1Molecular Genetics Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA 2Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain 3Transgenics Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA 4Cell Biology and Gene Expression Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA 5Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom 6Department of Pathophysiology, University of Tartu, Tartu, Estonia 7Computational Biology Group, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA 8Department of Neurology, Oslo University Hospital, Oslo, Norway 9Department of Neurology and Neurosurgery, Department of Human Genetics, McGill University, Montréal, Quebec, Canada 10Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montréal, Quebec, Canada 11Data Tecnica International, Glen Echo, Maryland, USA ABSTRACT studies, summary-data based Mendelian randomization Background: PD is a complex polygenic disorder.
  • Anti-FDX1 / Ferredoxin Antibody (ARG58670)

    Anti-FDX1 / Ferredoxin Antibody (ARG58670)

    Product datasheet [email protected] ARG58670 Package: 100 μl anti-FDX1 / Ferredoxin antibody Store at: -20°C Summary Product Description Rabbit Polyclonal antibody recognizes FDX1 / Ferredoxin Tested Reactivity Hu, Ms, Rat Tested Application IHC-P, WB Host Rabbit Clonality Polyclonal Isotype IgG Target Name FDX1 / Ferredoxin Antigen Species Human Immunogen Recombinant fusion protein corresponding to aa. 1-184 of Human FDX1 (NP_004100.1). Conjugation Un-conjugated Alternate Names LOH11CR1D; Hepatoredoxin; ADX; Adrenal ferredoxin; FDX; Ferredoxin-1; Adrenodoxin, mitochondrial Application Instructions Application table Application Dilution IHC-P 1:50 - 1:200 WB 1:200 - 1:500 Application Note * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Positive Control K562 Calculated Mw 19 kDa Observed Size 14 kDa Properties Form Liquid Purification Affinity purified. Buffer PBS (pH 7.3), 0.02% Sodium azide and 50% Glycerol. Preservative 0.02% Sodium azide Stabilizer 50% Glycerol Storage instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. www.arigobio.com 1/2 Note For laboratory research only, not for drug, diagnostic or other use. Bioinformation Gene Symbol FDX1 Gene Full Name ferredoxin 1 Background This gene encodes a small iron-sulfur protein that transfers electrons from NADPH through ferredoxin reductase to mitochondrial cytochrome P450, involved in steroid, vitamin D, and bile acid metabolism.
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
  • FCGR1A Recombinant Protein

    FCGR1A Recombinant Protein

    FCGR1A Recombinant Protein CATALOG NUMBER: 96-305 The purity of rh CD64 / FCGR1A was determined by DTT-reduced (+) SDS- PAGE and staining overnight with Coomassie Blue. Specifications SPECIES: Human SOURCE SPECIES: HEK293 cells SEQUENCE: Gln 16 - Pro 288 FUSION TAG: His Tag TESTED APPLICATIONS: WB APPLICATIONS: This recombinant protein can be used for WB. For research use only. BIOLOGICAL ACTIVITY: Measured by its ability to bind human IgG1 in the SPR assay (Biacore 2000) with the KD < 5 nM. Measured by its binding ability in a functional ELISA. Immobilized Human IgG4 at 10ug/mL (100 µl/well),can bind Human Fc gamma RI, His Tag (Cat# FCA-H52H2) with a linear of 0.1-2 ng/mL. Properties PURITY: >90% as determined by SDS-PAGE. PREDICTED MOLECULAR 32.5 kDa WEIGHT: PHYSICAL STATE: Lyopholized BUFFER: PBS, pH7.4 STORAGE CONDITIONS: Lyophilized Protein should be stored at -20˚C or lower for long term storage. Upon reconstitution, working aliquots should be stored at -20˚C or -70˚C. Avoid repeated freeze-thaw cycles. Additional Info ALTERNATE NAMES: FCGR1A, FCG1, FCGR1, IGFR1, CD64, CD64A, FCRI ACCESSION NO.: AAH32634 Background Receptors that recognize the Fc portion of IgG are divided into three groups designated Fc gamma RI, RII, and RIII, also known respectively as CD64, CD32, and CD16. Fc gamma RI binds IgG with high affinity and functions during early immune responses. Fc gamma RII and RIII are low affinity receptors that recognize IgG as aggregates surrounding multivalent antigens during late immune responses. High affinity immunoglobulin gamma Fc receptor I is also known as FCGR1A, FCG1, FCGR1, CD64 and IGFR1, is a type of integral membrane glycoprotein that binds monomeric IgG-type antibodies with high affinity, which belongs to the immunoglobulin superfamily or FCGR1 family.
  • The Concise Guide to Pharmacology 2019/20

    The Concise Guide to Pharmacology 2019/20

    Edinburgh Research Explorer THE CONCISE GUIDE TO PHARMACOLOGY 2019/20 Citation for published version: Cgtp Collaborators 2019, 'THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Transporters', British Journal of Pharmacology, vol. 176 Suppl 1, pp. S397-S493. https://doi.org/10.1111/bph.14753 Digital Object Identifier (DOI): 10.1111/bph.14753 Link: Link to publication record in Edinburgh Research Explorer Document Version: Publisher's PDF, also known as Version of record Published In: British Journal of Pharmacology General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 28. Sep. 2021 S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: Transporters. British Journal of Pharmacology (2019) 176, S397–S493 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Transporters Stephen PH Alexander1 , Eamonn Kelly2, Alistair Mathie3 ,JohnAPeters4 , Emma L Veale3 , Jane F Armstrong5 , Elena Faccenda5 ,SimonDHarding5 ,AdamJPawson5 , Joanna L